Hopefully, these trials will soon provide insights into the efficacy and safety of IL-6/IL-6R neutralization as a therapeutic strategy for reactivating the T cell compartment and combating tumor development in patients refractory to first-line immune checkpoint inhibitor-based therapies (Figure 5A, B). The gene discussed is IL6R; the disease is neoplasm.